Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(T)ides. Biological activities of the resulting adducts

Journal of Medicinal Chemistry
1986.0

Abstract

The covalent binding of the oxidized form of elliptinium acetate, an antitumor drug, to various ribonucleos(t)ides is described. In the absence of a strong nucleophile on the bases, e.g., a sulfhydryl group, the main target of this quinone imine derivative is the sugar moiety. With unmodified regular bases, the first electrophilic addition always occurs on the 2'-oxygen of ribose (more slowly for pyrimidine than for purine); in a second step, cyclization of the reoxidized product leads to a spiro derivative: only one stereoisomer is detected with purine nucleoside; the other stereoisomer appears as a minor product (10-20%) with nucleotides and pyrimidine nucleosides. With modified bases, no change is observed except for bases exhibiting an additional strong nucleophilic center: oxidized elliptinium alkylates thioguanine and thioguanosine on the sulfur atom and in this last case not on the ribose moiety. All spiro derivatives are less cytotoxic than the parent compound even if the base is an antimetabolite (azauridine); however, thio-elliptinium adducts maintain high cytotoxicity.

Knowledge Graph

Similar Paper

Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(T)ides. Biological activities of the resulting adducts
Journal of Medicinal Chemistry 1986.0
Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system
Journal of Medicinal Chemistry 1981.0
Autoxidation of the antitumor drug 9-hydroxyellipticine and its derivatives
Journal of Medicinal Chemistry 1983.0
Nucleosides and Nucleotides. 175. Structural Requirements of the Sugar Moiety for the Antitumor Activities of New Nucleoside Antimetabolites, 1-(3-C-Ethynyl-β-<scp>d</scp>-ribo-pentofuranosyl)cytosine and -uracil
Journal of Medicinal Chemistry 1998.0
Synthesis and antitumor activity of quaternary ellipticine glycosides, a series of novel and highly active antitumor agents
Journal of Medicinal Chemistry 1988.0
Ribose-Modified Purine Nucleosides as Ribonucleotide Reductase Inhibitors. Synthesis, Antitumor Activity, and Molecular Modeling of N<sup>6</sup>-Substituted 3′-C-Methyladenosine Derivatives
Journal of Medicinal Chemistry 2008.0
Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro
Journal of Medicinal Chemistry 1994.0
Antitumor Activity of C-Methyl-β-<scp>d</scp>-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors
Journal of Medicinal Chemistry 2005.0
Synthesis and antitumor activity of cis-dichloroplatinum(II)-N-aminated nucleoside
Journal of Medicinal Chemistry 1984.0
Basically substituted ellipticine analogs as potential antitumor agents
Journal of Medicinal Chemistry 1986.0